Calgary, Alberta – TheNewswire - August 18, 2025 - Ocumetics Technology Corp. (“Ocumetics” or the “Company”) (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO), a leader in advanced ophthalmic technology, is pleased to announce a monumental achievement in its mission to revolutionize vision correction: the successful implantation of its groundbreaking accommodating intraocular lens (the “Ocumetics Lens”) in human subjects.

“This is a moment of immense pride for our team and everyone who has believed in Ocumetics from the beginning,” said Dean Burns, President and CEO of Ocumetics. “For nearly two decades, we’ve been focused on a bold vision, one that many thought was out of reach. Our scientists, engineers, clinical advisors, and partners have poured their hearts into this innovation. Today we celebrate this success, but we know the work is far from done. There are millions of people waiting for us to get the Ocumetics Lens to market, and we are more driven than ever to bring this solution to the world.”

This achievement marks a major inflection point in the Company’s 18-year journey; one defined by relentless innovation, determination, and belief in the possibility of restoring dynamic vision. The procedures were completed without complications.  Early post-operative results will be available in several weeks and ongoing study results will be released over several months as they become available.  

“The Ocumetics accommodating intraocular lens has the potential to reshape the global standard of care first for cataract, and eventually, presbyopia patients,” adds Burns. “This milestone reinforces Ocumetics’ position as a leader in the next generation of ophthalmic innovation. With aging populations around the globe demanding better vision solutions, the potential impact of the Ocumetics Lens is profound.”

Unlike traditional monofocal or multifocal intraocular lenses, the Ocumetics Lens is designed to work with the natural movements of the eye, potentially restoring the ability to see both distant and near objects clearly without glasses or contacts following cataract surgery.

The Company will now continue its first-in-human clinical trial program, with additional implantations scheduled over the coming months. Each step brings Ocumetics closer to validating the safety and performance of the Ocumetics Lens, paving the way for regulatory approvals and broader clinical use.

Investors, partners, and medical professionals are encouraged to follow the Company’s updates as the clinical trial progresses.

About Ocumetics

Ocumetics Technology Corp. (TSXV: OTC) (OTCQB: OTCFF) (FRA: 2QBO) is a Canadian research and product development company that is dedicated to developing advanced vision correction solutions that enhance the quality of life for patients.  Through innovative research and development, Ocumetics aims to transform the field of ophthalmology with state-of-the-art intraocular lenses and other vision-enhancing technologies.

Ocumetics is in the preclinical study phase of a game-changing technology for the ophthalmic industry.  Ocumetics has developed an intraocular lens that fits within the natural lens compartment of the eye, potentially to eliminate the need for corrective lenses.  It is designed to allow the eye’s natural muscle activity to shift focus from distance to near, providing clear vision at all distances without the help of glasses or contact lenses.  

FOR FURTHER INFORMATION, PLEASE CONTACT:

Dean Burns                                

President and Chief Executive Officer        

(817) 874-7564           

Roger Jewett      

Chief Financial Officer             

This email address is being protected from spambots. You need JavaScript enabled to view it. 

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION 

This news release includes certain “forward-looking statements” under applicable Canadian securities legislation.  Forward-looking statements include, but are not limited to, statements with respect to the commencement, timing and scope of the research and development to be conducted by the Corporation mentioned above.  Forward-looking statements are necessarily based upon a number of estimates and assumptions that, while considered reasonable, are subject to known and unknown risks, uncertainties, and other factors which may cause the actual results and future events to differ materially from those expressed or implied by such forward-looking statements. Such factors include but are not limited to: operational matters, historical trends, current conditions and expected future developments, access to financing as well as other considerations that are believed to be appropriate in the circumstances.  There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements.  The Corporation disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.